Prior in vivo studies suggested that the overall net impact of host apoA‐I/HDL‐C levels on the tumor microenvironment is profound and manifold.16, 18, 19 We further made comparison between the differences in the immune signature of CRC patients with various HDL‐C levels. This evidence concerns the gene APOA1 and colorectal carcinoma.